SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CuraGen (CRGN) -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (363)10/14/2004 11:59:46 AM
From: keokalani'nui  Read Replies (2) | Respond to of 478
 
I'm sorry, but for the record...today's date is October 14, 2004. Now let's reread the press release....

CuraGen Corporation (Nasdaq: CRGN - News) today announced it has advanced CR011, a fully human monoclonal antibody-drug conjugate (ADC), which will be investigated as a potential treatment for metastatic melanoma, a deadly form of skin cancer. CuraGen anticipates that this promising therapeutic will enter clinical trials during the first half of 2006.